TGF-beta Antagonists for Premature Infant Lung Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bronchopulmonary dysplasia (BPD) in premature infants are inadequate, as they fail to effectively address the underlying lung development issues caused by elevated TGF-β levels, leading to disrupted alveologenesis and vasculogenesis, and existing studies have not directly investigated the role of TGF-β in the disease or its neutralization in premature infants.
Innovation Solution
Administration of a TGF-β antagonist, such as an anti-TGF-β antibody or soluble TGF-β receptor, during the perinatal period to inhibit TGF-β signaling and promote normal lung development in premature infants at risk of BPD, either directly to the infant or indirectly through the mother, to reduce the severity of the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for BPD are used, then infants receive standard care, but they fail to effectively address the underlying lung development issues caused by elevated TGF-β levels
Solution Approach 1:
The patent introduces TGF-β antagonists as intermediary substances that mediate between the harmful TGF-β signaling and the developing lung tissue. These antagonists specifically bind to TGF-β, preventing it from interacting with its receptors and thereby blocking the harmful effects on alveologenesis and vasculogenesis without interfering with other physiological processes
Solution Approach 2:
The patent changes the biochemical parameter of TGF-β signaling activity in the lung by introducing antagonists that reduce TGF-β binding to its receptors. This parameter change specifically addresses the elevated TGF-β levels characteristic of BPD while preserving normal lung development functions that depend on appropriate TGF-β signaling
2Reliability
If TGF-β antagonists are administered to inhibit TGF-β signaling, then lung development is protected, but the complexity of treatment increases
Solution Approach 1:
The TGF-β antagonist serves as a specific intermediary that targets only the pathological TGF-β signaling pathway. By using a highly specific molecular intermediary rather than broad-spectrum interventions, the treatment achieves precise protection of lung development with minimal off-target effects and simplified dosing regimens
Solution Approach 2:
The TGF-β antagonist works through self-service mechanisms where the drug molecule automatically binds to and neutralizes TGF-β molecules in the lung tissue. This self-targeting capability eliminates the need for complex delivery systems or activation mechanisms, simplifying the overall treatment approach while maintaining high efficacy
Data Source
Figure 1A~1D
Figure 2A~2F
Figure 3A~3D
AI summary
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.